OKYO Pharma’s (OKYO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of OKYO Pharma (NASDAQ:OKYO) in a report published on Monday morning,Benzinga reports. HC Wainwright currently has a $7.00 price target on the stock.

OKYO Pharma Stock Performance

Shares of OKYO opened at $1.09 on Monday. The firm has a 50-day moving average price of $1.09 and a 200 day moving average price of $1.07. OKYO Pharma has a 52-week low of $0.81 and a 52-week high of $1.90.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.